2017 / 05

Next Paper
DOI: 10.24075/brsmu.2017-05-02

ORIGINAL RESEARCH

Immunological memory formed in response to administration of GamTBvac recombinant tuberculosis vaccine candidate: clinical trials in healthy volunteers

Kleymenov DA1, Mazunina EP1, Lunin VG1, Koptev EYu1, Manuilov VA1,2, Gushchin VA1, Tkachuk AP1
About authors

1 Laboratory of Translational Biomedicine,
N. F. Gamaleya Federal Research Centre for Epidemiology and Microbiology, Moscow, Russia

2 Institute of Molecular Medicine,
I. M. Sechenov First Moscow State Medical University, Moscow, Russia

3 Department of Virology, Faculty of Biology,
Lomonosov Moscow State University, Moscow

Correspondence should be addressed: Denis A. Kleymenov
ul. Gamalei, d. 18, Moscow, Russia, 123098; ur.relbmar@tel00001

About paper

Funding: this work was supported by the Russian Ministry of Health and the Federal Agency for Scientific Organizations (state task no. 0574-2014-0023)

Contribution of the authors to this work: Kleymenov DA — analysis of literature, research planning, research preparation, data collection, analysis, and interpreatation, drafting of a manuscript, writing of a final version of a manuscript; Mazunina EP — analysis of literature, research planning, research preparation, data collection, analysis, and interpretation, drafting of a manuscript; Lunin VG — analysis of literature, research planning, research preparation, drafting of a manuscript; Koptev EYu, Manuilov VA — analysis of literature, research preparation, drafting of a manuscript; Gushchin VA — analysis of literature, research planning, research preparation, data analysis and interpretation, drafting of a manuscript, writing of a final version of a manuscript; Tkachuk AP — analysis of literature, research planning, research preparation, drafting of a manuscript, critical analysis of a manuscript.

Received: 2017-09-20 Accepted: 2017-10-20 Published online: 2018-01-13
|
  1. Kaufmann SHE, Weiner J, von Reyn CF. Novel approaches to tuberculosis vaccine development. Int J Infect Dis. 2017 Mar; 56: 263–7. DOI: 10.1016/j.ijid.2016.10.018.
  2. Nguipdop-Djomo P, Heldal E, Rodrigues LC, Abubakar I, Mangtani P. Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: A retrospective population-based cohort study. Lancet Infect Dis. 2016 Feb; 16 (2): 219–26. DOI: 10.1016/S1473-3099(15)00400-4
  3. World Health Organization. Global Tuberculosis Report 2016. 21th ed. Geneva: World Health Organization; 2016. 214 p.
  4. Glaziou P, Sismanidis C, Floyd K, Raviglione M. Global Epidemiology of Tuberculosis. Cold Spring Harb Perspect Med. 2015 Feb; 5 (2): a017798. DOI: 10.1101/cshperspect.a017798.
  5. O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiyskoy Federatsii v 2016 godu. National Report. Moscow: Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor); 2017. 220 p. Russian.
  6. Karp CL, Wilson CB, Stuart LM. Tuberculosis vaccines: Barriers and prospects on the quest for a transformative tool. Immunol Rev. 2015 Mar; 264 (1): 363–81. DOI: 10.1111/imr.12270. PubMed PMID: 25703572.
  7. Frick M. The Tuberculosis Vaccines Pipeline: A New Path to the Same Destination? [Internet]. 2015 Pipeline Report. HIV, HCV, and TB. London, NY: HIV i-Base/Treatment Action Group; July 2015 [cited 2017 Oct 9]. Available from: http://www.pipelinereport.org/2015/tb-vaccines.
  8. Tkachuk AP, Gushchin VA, Potapov VD, Demidenko AV, Lunin VG, Gintsburg AL. Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models. PLoS One. 2017; 12 (4): e0176784. DOI: 10.1371/journal.pone.0176784.
  9. Evaluation of the Safety and Immunogenicity of the Recombinant Subunit Vaccine "GamTBvac" Against the Tuberculosis [Internet]. U.S. National Library of Medicine. ClinicalTrials.gov Identifier: NCT03255278 [cited 2017 Oct 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT03255278.
  10. ICH Harmonised Tripartite Guideline. Guideline for good clinical practice E6(R1). Current Step 4 version. Dated 10 June 1996 [Internet]. [cited 2017 Oct 9]: [59 p.]. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf.
  11. Federal'nyy zakon ot 12.04.2010 № 61-FZ (red. ot 03.07.2016) «Ob obrashchenii lekarstvennykh sredstv». Federal law of the Russian Federation. Russian.
  12. GOST 33044-2014 Printsipy nadlezhashchey laboratornoy praktiki. Mezhgosudarstvennyy standart. Data vvedeniya: 1 avgusta 2015 g. State Standard. Identical to OECD Guide 1:1998 OECD Principles of good laboratory practice. Russian.
  13. Prikaz Ministerstva zdravookhraneniya RF ot 1 aprelya 2016 g. № 200n «Ob utverzhdenii pravil nadlezhashchey klinicheskoy praktiki». Order of the Ministry of Healthcare of the Russian Federation. Russian.
  14. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005 Dec 16; 54 (RR-15): 49–55.
  15. QuantiFERON-TB Gold Plus (QFT-Plus) ELISA Package Insert. Rev. 04. Hilden: QIAGEN GmbH; Feb 2016.
  16. Melikhov OG, Atarshchikov DS. Nezhelatel'nye yavleniya v klinicheskikh issledovaniyakh lekarstvennykh sredstv. Kachestvennaya klinicheskaya praktika. 2003; (2): 11–6. Russian.
  17. Lalvani A, Brookes R, Wilkinson RJ, Malin AS, Pathan AA, Andersen P, et al. Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 1998 Jan 6; 95 (1): 270–5. PubMed PMID: 9419365.
  18. Dewan PK, Grinsdale J, Liska S, Wong E, Fallstad R, Kawamura LM. Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infect Dis. 2006 Mar 15; 6: 47. PubMed PMID: 16539718.
  19. Plekhanova MA, Аksenova VA, Tkachuk AP, Patsula YI, Krivtsova LA, Kolomeets AN. Evaluation of specific antigens at the early stage of tuberculous infection in children. Tuberkulez i bolezni legkikh. 2017; 95 (1): 27–33. Russian.
  20. Luminex. The xMAP Cookbook. A collection of methods and protocols for developing multiplex assays with xMAP Technology. 3rd ed. [Internet]; [cited 2017 May 5]. Available from: http://info.luminexcorp.com/en-us/download-the-xmap-cookbook.
  21. Luabeya AKK, Kagina BMN, Tameris MD, Geldenhuys H, Hoff ST, Shi Z, et al. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine. 2015 Aug 7; 33 (33): 4130–40. DOI: 10.1016/j.vaccine.2015.06.051.
  22. Geldenhuys H, Mearns H, Miles DJC, Tameris M, Hokey D, Shi Z, et al. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial. Vaccine. 2015 Jul 9; 33 (30): 3592–9. DOI: 10.1016/j.vaccine.2015.05.036.
  23. Reither K, Katsoulis L, Beattie T, Gardiner N, Lenz N, Said K, et al. Safety and immunogenicity of H1/IC31H®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: A phase II, multi-centre, double-blind, randomized, placebo-controlled trial. PLoS One. 2014; 9 (12): e114602. DOI: 10.1371/journal.pone.0114602.
  24. Lu LL, Chung AW, Rosebrock TR, Ghebremichael M, Yu WH, Grace PS, et al. A Functional Role for Antibodies in Tuberculosis. Cell. 2016 Oct 6; 167 (2): 433–43.e14. DOI: 10.1016/j.cell.2016.08.072.